Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.32 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20746861 | 0.77 | ROCK2 (0.40) | RXRAGRIN1GRIN2BKCNT1 | |
| SCHEMBL24908516 | 0.73 | EPHX2 (0.42) | RXRAGRIN1GRIN2BKCNT1 | |
| SCHEMBL19538977 | 0.70 | RXRA (0.38) | RXRAGRIN1GRIN2B | |
| SCHEMBL21064022 | 0.67 | RXRA (0.36) | RXRAGRIN1GRIN2B | |
| SCHEMBL21775969 | 0.67 | EPHX2 (0.46) | RXRAGRIN1GRIN2BKCNT1 | |
| SCHEMBL18878403 | 0.67 | NPC1 (0.47) | RXRAGRIN1GRIN2BKCNT1 | |
| SCHEMBL2609427 | 0.67 | KDM5B (0.48) | RXRAGRIN1GRIN2BKCNT1 | |
| SCHEMBL14328380 | 0.66 | NOTUM (0.48) | RXRAGRIN1GRIN2B | |
| SCHEMBL12351974 | 0.66 | GAA (0.53) | — | |
| SCHEMBL13160234 | 0.66 | NOTUM (0.36) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RXRA 3422/4885GRIN1 4440/4885GRIN2B 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.